E353: Why Biotech Is Struggling in Today’s Market (and the Future of Healthcare)

About this episode

David Weisburd interviews David Berry about the challenges in the biotech industry and the future of healthcare innovation.

What if the biggest opportunity in healthcare isn’t new drugs—but reinventing how the entire system works? In this episode, I sit down with David Berry, Founder of over 20 companies including seven $1B+ businesses, to discuss why the traditional biotech model is breaking and where the next wave of innovation in healthcare is emerging. David explains how pricing pressure, rising costs, and global competition are compressing returns in drug development, while AI, data, and new business models are unlocking entirely new ways to deliver care. We also explore how technology is transforming clinical trials, why healthcare is shifting beyond pharmaceuticals, and how investors can find opportunity in mispriced parts of the market.

People in this episode

Host: David Weisburd

Guest: David Berry

Topics covered

• biotech
• healthcare innovation
• drug development
• AI in healthcare
• clinical trials
• investment opportunities

Keywords

• biotech
• healthcare
• drug development
• AI
• clinical trials
• investment
• innovation

Mentioned in this episode

Organizations: biotech, healthcare

More episodes of How I Invest with David Weisburd

• E389: The Future of Investing: Data Centers, AI & the Next Trillion-Dollar Companies · June 12, 2026 · 50 min
• E388: The Future of Investing: AI, Expert Networks, and Information Alpha · June 11, 2026 · 34 min
• E387: Where Alpha Hides in Private Equity | Josh Adams · June 10, 2026 · 35 min
• E386: Adams Street ($70B): Venture Capital Has a New Problem · June 9, 2026 · 39 min
• E385: Why Public Markets Need SpaceX, OpenAI & Anthropic · June 8, 2026 · 28 min
• E384: CEO of Commonfund on Venture Capital, Power Laws & the Future of IPOs · June 5, 2026 · 41 min